Key regions: France, Europe, United Kingdom, Brazil, India
The Oncology Drugs market in ASEAN has been experiencing significant growth in recent years, driven by various factors such as increasing cancer prevalence, rising healthcare expenditure, and advancements in technology and research.
Customer preferences: Patients in ASEAN countries generally prefer targeted therapies and immunotherapies over traditional chemotherapy due to their better efficacy and fewer side effects. Additionally, there is a growing demand for personalized medicine and precision oncology, which involves tailoring treatment plans based on the patient's genetic makeup and disease characteristics.
Trends in the market: Indonesia and Vietnam are expected to be the fastest-growing markets for oncology drugs in ASEAN due to their large populations and increasing cancer burden. Singapore and Malaysia, on the other hand, have more developed healthcare systems and are likely to see a higher uptake of innovative therapies. In terms of drug classes, immunotherapies and targeted therapies are expected to continue dominating the market, while biosimilars are gaining traction as a more affordable alternative to branded biologics.
Local special circumstances: Despite the overall positive outlook, there are some challenges in the ASEAN region that may impact the growth of the oncology drugs market. One of them is the lack of access to healthcare in some rural areas, which can lead to late diagnosis and poor treatment outcomes. Additionally, the high cost of innovative therapies may limit their availability to only a small portion of the population. Finally, regulatory hurdles and intellectual property issues may hinder the entry of new players and limit competition in the market.
Underlying macroeconomic factors: The oncology drugs market in ASEAN is closely tied to the region's macroeconomic conditions, particularly the level of healthcare expenditure and government policies. As ASEAN countries continue to develop and grow, there is likely to be an increasing demand for healthcare services, including cancer treatment. However, the affordability and accessibility of these services will depend on various factors such as GDP per capita, healthcare infrastructure, and insurance coverage. Additionally, government policies around drug pricing and reimbursement will play a crucial role in shaping the market dynamics.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
